| Literature DB >> 21589757 |
H N Aswatha Ram1, Prachiti Lachake, Ujjwal Kaushik, C S Shreedhara.
Abstract
BACKGROUND: Floating tablets prolong the gastric residence time of drugs, improve bioavailability, and facilitate local drug delivery to the stomach. With this objective, floating tablets containing aqueous extract of liquorice as drug was prepared for the treatment of Helicobacter pylori and gastric ulcers.Entities:
Keywords: Buoyancy time; floating tablets; korsemeyer; liquorice extract
Year: 2010 PMID: 21589757 PMCID: PMC3093044 DOI: 10.4103/0974-8490.72329
Source DB: PubMed Journal: Pharmacognosy Res ISSN: 0974-8490
HPTLC of liquorice extract
| Track | Peak | Rf | Peak area | Volume µL | |
|---|---|---|---|---|---|
| 1 | 1 | 0.23 | 5139.3 | 2 | |
| 2 | 1 | 0.21 | 4801.7 | 2 | |
| 3 | 2 | 0.2 | 6454 | 3 | |
| 4 | 2 | 0.2 | 7763 | 4 | |
| 5 | 2 | 0.18 | 743.8 | 2 | |
| 6 | 2 | 0.18 | 1111.6 | 3 | |
| 7 | 2 | 0.18 | 1309.9 | 4 |
Composition of floating tablet formulations
| Ingredients mg | F1 | F2 | F3 | F4 | F5 | F6 | F7 |
|---|---|---|---|---|---|---|---|
| Liquorice extract | 250 | 250 | 250 | 250 | 250 | 250 | 250 |
| Psyllium husk | 75 | 100 | 125 | 100 | 100 | 100 | 100 |
| HPMC K100M | 50 | 50 | 50 | 40 | 60 | 50 | 50 |
| Sodium bicarbonate | 100 | 100 | 100 | 100 | 100 | 90 | 110 |
| Talc | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Magnesium stearate | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Evaluation of formulated tablets
| Formulation | Diameter (mm) | Thickness (mm) | Hardness (kg/cm2) | Friability (%) | Uniformity of weight (mg) | Drug content (%) | Buoyancy time (minutes) |
|---|---|---|---|---|---|---|---|
| F1 | 11.166±0.115 | 4.02±0.01 | 3.133±0.251 | 0.85±0.032 | 500.4±0.683 | 97.273±0.499 | 5±0.288 |
| F2 | 11.533±0.208 | 4.066±0.011 | 3.1±0.2 | 0.868±0.022 | 525.3±0.575 | 98.026±0.902 | 4.5±0.5 |
| F3 | 11.933±0.152 | 4.086±0.005 | 3.4±0.264 | 0.726±0.045 | 550.665±0.745 | 98.277±0.662 | 4±0.763 |
| F4 | 11.3±0.1 | 4.036±0.025 | 3.366±0.23 | 0.716±0.093 | 515.285±0.736 | 99.61±0.631 | 4±0.866 |
| F5 | 11.733±0.115 | 4.073±0.015 | 3.333±0.208 | 0.804±0.076 | 535.16±0.752 | 97.442±0.521 | 5±0.577 |
| F6 | 11.4±0.2 | 4.046±0.02 | 3.466±0.057 | 0.811±0.091 | 515.22±0.689 | 96.107±0.382 | 3.5±0.5 |
| F7 | 11.7±0.264 | 4.07±0.02 | 3.5±0.1 | 0.675±0.043 | 535.235±0.605 | 99.527±0.661 | 5±0.763 |
Analysis of release mechanism
| Formulation | Zero order R2 | First order R2 | First order k (h-1) | Higuchi R2 | Korsemeyer R2 | Korsemeyer n |
|---|---|---|---|---|---|---|
| F1 | 0.9668 | 0.9049 | 0.2025 | 0.9794 | 0.9973 | 0.6893 |
| F2 | 0.9751 | 0.9219 | 0.1596 | 0.9738 | 0.9904 | 0.6788 |
| F3 | 0.9507 | 0.7858 | 0.3085 | 0.9908 | 0.9973 | 0.6241 |
| F4 | 0.945 | 0.9379 | 0.2234 | 0.9865 | 0.9949 | 0.635 |
| F5 | 0.9698 | 0.9361 | 0.2062 | 0.9714 | 0.9954 | 0.7177 |
| F6 | 0.9503 | 0.9161 | 0.2445 | 0.9799 | 0.9817 | 0.7295 |
| F7 | 0.9912 | 0.9241 | 0.1751 | 0.9523 | 0.9982 | 0.8408 |
Figure 1Comparative drug release profile of tablet formulations F1, F2 and F3
Figure 2Comparative drug release profile of tablet formulations F4 and F5
Figure 3Comparative drug release profile of tablet formulations F6 and F7
| First run | chloroform-acetone (9:1) | |
| Second run | chloroform-diethyl etherformic acid (80:15:1) |